Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study.

Plain-language guide to PMID 20404743 (2010): open-label randomized controlled trial of Angiotensin II, low blood pressure and orthostatic hypotension.

Key Facts

PMID: 20404743
Journal: Journal of hypertension
Year: 2010
Study type: Randomized Controlled Trial
Authors: Kario K et al. (8 authors)
DOI: 10.1097/HJH.0b013e3283395267

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Angiotensin II in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The researchers conducted an open-label multicenter trial, the J-TOP study, that enrolled 450 hypertensives with self-measured systolic HBP more than 135 mmHg.

The study patients were stratified into three groups according to the difference between their morning and evening SBPs difference: a morning hypertension group (morning and evening difference at least 15 mmHg; n = 170), a morning and evening hypertension group (0 mmHg < or = morning and evening difference <15 mmHg; n = 198), and an evening hypertension group (morning and evening difference <0 mmHg; n = 82).

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Being open-label, the Angiotensin II study did not mask who received what.

Running at several centres spread the Angiotensin II study over different clinics and patient groups.

The 6-month change in the urinary albumin/creatinine ratio (UACR) was assessed.

What Was Measured

PubMed files the paper under topics including Albuminuria, Angiotensin Receptor Antagonists, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Blood Pressure and Clinical Protocols.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Angiotensin II in people with low blood pressure and orthostatic hypotension.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Journal of hypertension), a journal based in Netherlands.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.

Our Notes on the Compound

Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.